Premium
A randomized placebo‐controlled trial of preoperative tranexamic acid among women undergoing elective cesarean delivery
Author(s) -
Maged Ahmed M.,
Helal Omneya M.,
Elsherbini Moutaz M.,
Eid Marwa M.,
Elkomy Rasha O.,
Dahab Sherif,
Elsissy Maha H.
Publication year - 2015
Publication title -
international journal of gynecology and obstetrics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.895
H-Index - 97
eISSN - 1879-3479
pISSN - 0020-7292
DOI - 10.1016/j.ijgo.2015.05.027
Subject(s) - medicine , tranexamic acid , hematocrit , placebo , anesthesia , randomized controlled trial , cesarean delivery , blood loss , surgery , elective surgery , pregnancy , blood transfusion , alternative medicine , pathology , biology , genetics
Objective To study the efficacy and safety of preoperative intravenous tranexamic acid to reduce blood loss during and after elective lower‐segment cesarean delivery. Methods A single‐blind, randomized placebo‐controlled study was undertaken of women undergoing elective lower‐segment cesarean delivery of a full‐term singleton pregnancy at a center in Cairo, Egypt, between November 2013 and November 2014. Patients were randomly assigned (1:1) using computer‐generated random numbers to receive either 1 g tranexamic acid or 5% glucose 15 minutes before surgery. Preoperative and postoperative complete blood count, hematocrit values, and maternal weight were used to calculate the estimated blood loss (EBL) during cesarean, which was the primary outcome. Analyses included women who received their assigned treatment, whose surgery was 90 minutes or less, and who completed follow‐up. Results Analyses included 100 women in each group. Mean EBL was significantly higher in the placebo group (700.3 ± 143.9 mL) than in the tranexamic acid group (459.4 ± 75.4 mL; P < 0.001). Only six women, all in the placebo group, experienced an EBL of more than 1000 mL. There were no reports of thromboembolic events up to 4 weeks postoperatively. Conclusion Preoperative administration of tranexamic acid safely reduces blood loss during elective lower‐segment cesarean delivery. Australian New Zealand Clinical Trials Registry: ACTRN12615000312549.